EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Instil Bio's enterprise value is $5.81 Mil.
Instil Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-146.12 Mil. Therefore, Instil Bio's EV-to-EBITDA for today is -0.04.
The historical rank and industry rank for Instil Bio's EV-to-EBITDA or its related term are showing as below:
TIL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -93.03 Med: -0.11 Max: 6.33
Current: -0.04
During the past 5 years, the highest EV-to-EBITDA of Instil Bio was 6.33. The lowest was -93.03. And the median was -0.11.
TIL's EV-to-EBITDA is ranked worse than 100% of 474
companies
in the Biotechnology industry
Industry Median: 9.165
vs TIL: -0.04
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), Instil Bio's stock price is $10.71.
Instil Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-24.000. Therefore, Instil Bio's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Instil Bio EV-to-EBITDA Historical Data
The historical data trend for Instil Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Instil Bio's EV-to-EBITDA
For the Biotechnology subindustry, Instil Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instil Bio's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Instil Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Instil Bio's EV-to-EBITDA falls into.
Instil Bio EV-to-EBITDA Calculation
Instil Bio's EV-to-EBITDA for today is calculated as:
Instil Bio's current Enterprise Value is $5.81 Mil.
Instil Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-146.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instil Bio (NAS:TIL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Instil Bio's share price for today is $10.71.
Instil Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Instil Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TIL has been successfully added to your 